US20200345374A1 - Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery - Google Patents
Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery Download PDFInfo
- Publication number
- US20200345374A1 US20200345374A1 US16/933,651 US202016933651A US2020345374A1 US 20200345374 A1 US20200345374 A1 US 20200345374A1 US 202016933651 A US202016933651 A US 202016933651A US 2020345374 A1 US2020345374 A1 US 2020345374A1
- Authority
- US
- United States
- Prior art keywords
- blood vessel
- occluding
- patient
- stent
- weight loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12027—Type of occlusion
- A61B17/12031—Type of occlusion complete occlusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12027—Type of occlusion
- A61B17/12036—Type of occlusion partial occlusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12027—Type of occlusion
- A61B17/1204—Type of occlusion temporary occlusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12136—Balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/1214—Coils or wires
- A61B17/12145—Coils or wires having a pre-set deployed three-dimensional shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
- A61B17/12172—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
- A61F5/0013—Implantable devices or invasive measures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12009—Implements for ligaturing other than by clamps or clips, e.g. using a loop with a slip knot
- A61B17/12013—Implements for ligaturing other than by clamps or clips, e.g. using a loop with a slip knot for use in minimally invasive surgery, e.g. endoscopic surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/122—Clamps or clips, e.g. for the umbilical cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/852—Two or more distinct overlapping stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2002/826—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents more than one stent being applied sequentially
Definitions
- This invention relates to surgical methods and apparatus in general, and more particularly to surgical and non-surgical methods and apparatus for treating a patient by intentionally occluding a blood vessel, including a catheter-based method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery.
- Obesity is a serious medical condition. Complications associated with obesity include hypertension, diabetes, coronary artery disease, stroke, congestive heart failure, multiple orthopedic problems, pulmonary insufficiency, etc. Obesity can significantly affect quality of life and can result in a markedly decreased life expectancy.
- the present invention provides a novel method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery.
- the present invention also provides a novel method and apparatus for inducing weight loss in a patient by intentionally occluding a blood vessel other than the celiac artery, and/or in addition to the celiac artery.
- the present invention provides a novel method and apparatus for treating a patient for purposes other than inducing weight loss in the patient by intentionally occluding a blood vessel.
- a method for inducing weight loss in a patient comprising:
- apparatus for occluding a blood vessel comprising a two-part composite stent occluder comprising (i) an exterior, endothelializing support stent, and (ii) an interior, occluding stent comprising a loose weave fabric windsock.
- apparatus for occluding a blood vessel comprising a two-part composite stent occluder comprising (i) an exterior, endothelializing support stent, and (ii) an interior, progressively-occluding element.
- a method for providing treatment to a patient comprising:
- FIG. 1 is a schematic view showing one preferred location for occluding the celiac artery in order to induce weight loss in a patient;
- FIG. 2 is a schematic view showing a ligating suture for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient;
- FIG. 3 is a schematic view showing a ligating clip for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient;
- FIG. 4 is a schematic view showing an occluding stent for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient;
- FIG. 4A is a sectional view taken along line 4 A- 4 A of FIG. 4 ;
- FIG. 5 is a schematic view showing an occluding umbrella device for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient;
- FIG. 5A is a sectional view taken along line 5 A- 5 A of FIG. 5 ;
- FIG. 6 is a schematic view showing a two-part composite stent occluder for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient;
- FIGS. 7-10 are schematic views showing deployment of the two-part composite stent occluder of FIG. 6 ;
- FIGS. 11-13 are schematic views showing withdrawal of the two-part composite stent occluder of FIG. 6 ;
- FIG. 14 is a schematic view showing a modified form of the two-part composite stent occluder of FIG. 6 ;
- FIGS. 15 and 16 are schematic views showing another two-part composite stent occluder for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient;
- FIGS. 17 and 18 are schematic views showing the two-part composite stent occluder of FIGS. 15 and 16 closing down so as to occlude a blood vessel.
- the present invention provides a novel method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery.
- the present invention also provides a novel method and apparatus for inducing weight loss in a patient by intentionally occluding a blood vessel other than the celiac artery, and/or in addition to the celiac artery.
- the present invention provides a novel method and apparatus for treating a patient for purposes other than inducing weight loss in the patient by intentionally occluding a blood vessel.
- weight loss is induced in a patient by intentionally occluding the celiac artery in order to create hypoperfusion in the stomach, whereby to induce weight loss in the patient.
- the celiac artery supplies oxygenated blood to the stomach, liver, pancreas, spleen and to the superior half of the duodenum.
- the celiac artery is a major source of blood for the stomach, inasmuch as the other blood vessels supplying nourishment to the stomach provide adequate flow to maintain viability, but cannot provide the marked increase in blood flow seen in the post-prandial period.
- the celiac artery is intentionally reversibly occluded gradually over time in order to create hypoperfusion in the stomach (and/or other gastrointestinal organs serviced by the celiac artery) so as to interfere with normal gastrointestinal function and thereby induce weight loss in the patient.
- Occlusion is preferably effected at a location where it will only interfere with gastrointestinal function and will not seriously impede other essential anatomical functions.
- occlusion may be effected in the trunk of the celiac artery, e.g., at the location 5 shown in FIG. 1 .
- occlusion may be effected in branches of the celiac artery (e.g., the left or right gastric arteries, the left or right gastroepiploic arteries, the common hepatic artery, and/or other celiac artery branches).
- branches of the celiac artery e.g., the left or right gastric arteries, the left or right gastroepiploic arteries, the common hepatic artery, and/or other celiac artery branches).
- occlusion may be intentionally induced in other blood vessels servicing the organs of the gastrointestinal tract, whereby to impede normal gastrointestinal function and thereby induce weight loss in the patient.
- occlusion may be intentionally induced in other mesenteric vessels (e.g., the superior mesenteric artery and/or its major branches), and/or mesenteric veins, etc.
- the present invention comprises the intentional occlusion of substantially any blood vessel servicing the gastrointestinal tract such that the occlusion diminishes normal gastrointestinal function, whereby to induce weight loss in the patient.
- One preferred form of the present invention comprises the intentional occlusion of the celiac artery (including one or more of its branches) so as to diminish gastrointestinal function and thereby induce weight loss in the patient.
- Occlusion may be effected by constricting blood flow through the target blood vessel using an external occluding device, i.e., by applying an external occluding device against the outer surf ace of the blood vessel and causing the blood vessel to close down so as to occlude its internal lumen.
- an external occluding device i.e., by applying an external occluding device against the outer surf ace of the blood vessel and causing the blood vessel to close down so as to occlude its internal lumen.
- the target blood vessel may be occluded using a ligating suture 10 comprising a knot 15 .
- the target blood vessel may be occluded using a ligating clip 20 .
- the target blood vessel may be occluded using other external occluding devices which will be apparent to those skilled in the art in view of the present disclosure.
- occlusion is preferably effected by deploying the external occluding device against the exterior surface of the target blood vessel via minimally invasive (e.g., laparoscopic) surgery.
- Occlusion may also be effected by constricting blood flow through the target blood vessel using an internal occluding device, i.e., by deploying an internal occluding device within the internal lumen of a blood vessel so as to restrict blood flow through the internal lumen of the blood vessel.
- the target blood vessel may be occluded using an occluding stent 25 which comprises an occluding element 30 which intrudes across the lumen of the blood vessel which receives the occluding stent 25 .
- the target blood vessel may be occluded using an erectable “occluding umbrella” device 35 which spans the lumen of the blood vessel.
- the target blood vessel may be occluded using a two-part composite stent occluder 40 comprising (i) an exterior, endothelializing support stent 45 (e.g., comprising a skeleton 50 covered by fabric 55 ), and (ii) an interior, removable occluding stent 60 (e.g., comprising a skeleton 65 containing a loose weave fabric “windsock” 70 for clotting off with blood and thereby occluding the blood vessel).
- a two-part composite stent occluder 40 comprising (i) an exterior, endothelializing support stent 45 (e.g., comprising a skeleton 50 covered by fabric 55 ), and (ii) an interior, removable occluding stent 60 (e.g., comprising a skeleton 65 containing a loose weave fabric “windsock” 70 for clotting off with blood and thereby occluding the blood vessel).
- the exterior endothelializing support stent 45 is deployed in the target blood vessel (e.g., the celiac artery) first, and then the interior occluding stent 60 is thereafter deployed within (and removably mounted to) the exterior endothelializing support stent 45 , with the interior occluding stent 60 thereafter clotting off over time.
- This construction has the advantage that the interior occluding stent 60 can be readily removed from the blood vessel at a later time, whereby to restore blood flow through the blood vessel. See, for example, FIGS. 11-13 , which show withdrawal of the interior occluding stent 60 from the target blood vessel (e.g., the celiac artery).
- FIG. 14 shows a variation of the two-part composite stent occluder of FIGS. 6-13 , wherein the interior occluding stent 60 comprises the aforementioned skeleton 65 and an inflatable occluding balloon 75 which is disposed within skeleton 65 .
- interior occluding stent 60 is preferably removably disposed within the exterior endothelializing support stent 45 .
- the target blood vessel may be occluded using other internal occluding devices which will be apparent to those skilled in the art in view of the present disclosure.
- occlusion is preferably effected by positioning the internal occluding device within the target blood vessel via an endoluminal approach.
- Occlusion of the target blood vessel may be partial or total.
- the occluding device is configured so as to permit the creation of a partial occlusion, e.g., the ligating suture 10 of FIG. 2 and/or the ligating clip 20 of FIG. 3 may be configured to apply just enough force to reduce, but not completely block, blood flow through the target blood vessel; and/or the occluding stent 25 of FIGS. 4 and 4A , and/or the erectable “occluding umbrella” device of FIGS. 5 and 5A , and/or the two-part composite stent occluder 40 of FIGS.
- occluding element 30 may include holes 80
- umbrella device 35 of FIGS. 5 and 5A the umbrella device may include holes 85 .
- the loose weave fabric “windsock” 70 may be configured to clot off only a portion of the lumen of the blood vessel, and/or with the two-part composite stent occluder 40 of FIG. 14 , inflatable occluding balloon 7 S may be configured to close off only a portion of the lumen of the blood vessel.
- Occlusion may be permanent or temporary.
- the occluding device e.g., the ligating suture 10 of FIG. 2 , the ligating clip 20 of FIG. 3 , the occluding stent 25 of FIGS. 4 and 4A , the erectable “occluding umbrella” device 3 S of FIGS. 5 and 5A , and/or the internal component of the two-part composite stent occluder 40 of FIGS. 6-13 and/or FIG. 14
- the occluding device may be configured so that the occluding device is removable at some time in the future, so that normal blood flow through the target blood vessel may be restored.
- some or all of the occluding devices may be formed out of a biodegradable or bioabsorbable material, so that the occluding device will automatically cease its occlusive function at some time in the future.
- the degree of occlusion may also be adjusted over time.
- the degree of occlusion may be increased and/or decreased over time, in order to adjust the level of hypoperfusion created in the stomach (and/or other gastrointestinal organ), whereby to selectively adjust the gastrointestinal function of the patient.
- the degree of occlusion may be reduced so as to increase gastrointestinal function.
- the degree of occlusion may be increased so as to further decrease gastrointestinal function.
- a total occlusion may subsequently be partially re-opened or fully re-opened, a partial narrowing can be made more or less restrictive, a restrictive narrowing can be made totally occlusive, etc.
- an occluding device that causes slow progressive occlusion over time may be highly desirable.
- this progressive occluding device could be an encircling suture 10 ( FIG. 2 ) and/or ligating clip 20 ( FIG. 3 ) containing a hygroscopic material (e.g., Ameroid or the like)—the progressive occluding device could be placed laparoscopically about the exterior surface of the target blood vessel, and the hygroscopic material would then swell over time, resulting in a relatively slow, progressive occlusion of the target blood vessel.
- a hygroscopic material e.g., Ameroid or the like
- the progressive occluding device could be an occluding stent 25 ( FIGS. 4 and 4A ) and/or an occluding umbrella device 35 containing hygroscopic material that would slowly swell over time, ultimately resulting in vessel narrowing or even complete vessel occlusion.
- the progressive occluding structure could be a stent containing a diaphanous fiber mesh that slowly clots off and/or endothelializes off over time and becomes occlusive—see, for example, the interior occluding stent 60 of FIGS.
- the ability to reverse the occlusion or narrowing of the target blood vessel may be important in many situations.
- the physician could use laparoscopic instruments to remove the externally compressive or restrictive device (e.g., the encircling suture 10 of FIG. 2 , the ligating clip 20 of FIG. 3 , etc.) at a time determined to optimize patient benefit and minimize adverse outcomes.
- the externally compressive or restrictive device e.g., the encircling suture 10 of FIG. 2 , the ligating clip 20 of FIG. 3 , etc.
- the physician could use catheters, wires and inflatable balloons to re-open an occluding stent (e.g., the occluding stent 25 of FIGS. 4 and 4A ), occluding umbrella (e.g., the occluding umbrella device 35 of FIGS. 5 and 5A ), endothelialized stent (e.g., with the two-part composite stent occluder 40 of FIGS. 6-13 , or with the two-part composite stent occlude 40 of FIG. 14 , the interior occluding stent could be removed), etc.
- the therapy would spontaneously, autonomously and progressively reverse due to the use of biodegradable or bioabsorbable components in the external occluding device and/or the internal occluding device.
- the occluding device comprises the two-part composite stent occluder 40 of FIGS. 6-13 in which an exterior stent is first placed in the target blood vessel, with an interior occluding (or gradually occluding) fabric-covered stent thereafter being placed coaxially within the exterior endothelializing support stent (see FIGS. 7-10 ).
- the interface between the two components could be designed to block tissue in-growth, so that the two stents could be readily separated at a later time.
- the interior occluding stent would be removed (for example, collapsed down into a catheter) and the exterior endothelializing support stent would stay behind in the patient indefinitely (see FIGS. 11-13 ).
- two-part stent occluder 90 comprises an exterior, endothelializing support stent 95 and an interior, progressively-occluding element 100 which together form a generally tubular structure having a central lumen 105 extending therethrough.
- exterior, endothelializing support stent 95 preferably comprises a cylindrical Nitinol skeleton 110 covered by fabric 115 .
- interior, progressively-occluding element 100 preferably comprises an envelope 120 formed in the shape of a hollow cylinder and comprising (i) an exterior wall 125 connected to exterior, endothelializing support stent 95 , (ii) an interior wall 130 spaced from exterior wall 125 , (iii) a first end seal 135 , and (iv) a second end seal 140 , whereby to define a cylindrical chamber 145 between exterior and interior walls 125 , 130 and first end seal 135 and second end seal 140 .
- Chamber 145 is filled with a hygroscopic material 150 (e.g., a shape memory polymer which can absorb many times its own volume in water, so as to thereby dramatically increase in volume).
- a hygroscopic material 150 e.g., a shape memory polymer which can absorb many times its own volume in water, so as to thereby dramatically increase in volume.
- Envelope 120 is preferably formed out of a water-impermeable material such as ePTFE (e.g., 2-4 mils thick), and includes a plurality of tiny holes 155 (e.g., 0.05 mils in diameter). Tiny holes 155 permit water (but little else) to very slowly penetrate into chamber 145 and mix with hygroscopic material 150 , whereby to expand the volume of the hygroscopic material 150 , as will hereinafter be discussed.
- ePTFE e.g., 2-4 mils thick
- Tiny holes 155 permit water (but little else) to very slowly penetrate into chamber 145 and mix with hygroscopic material 150 , whereby to expand the volume of the hygroscopic material 150 , as will hereinafter be discussed.
- two-part stent occluder 90 is disposed in the lumen of the blood vessel which is to be occluded (e.g., the celiac artery) so that exterior, endothelializing support stent 95 engages and is secured to the inner wall of the blood vessel.
- blood passes easily through lumen central 105 of two-part stent occlude 90 .
- water in the blood of the patient passes through the tiny holes 155 in envelope 120 and enters chamber 145 , where it contacts hygroscopic material 150 .
- two-part stent occluder 90 can occlude a blood vessel so as to treat a patient (e.g., for weight loss), and this occlusion can be effected on a gradual basis.
- a conventional plastically deformable balloon expandable metallic stent (not shown), or any other appropriate stent or stent-like device, may be deployed within the central lumen 105 of the occluded two-part stent occluder 90 .
- the conventional plastically deformable balloon expandable metallic stent As the conventional plastically deformable balloon expandable metallic stent is expanded, it engages the narrowed interior wall 130 of envelope 120 and drives it radially outward with substantial force. This action applies a compressive force to the water-swollen hygroscopic material 145 , thereby forcing water out of the hygroscopic material 145 (e.g., in the manner of squeezing a sponge).
- first end seal 135 and/or second end seal 140 of envelope 120 will rupture at predetermined zones, thereby allowing the hygroscopic material 145 to rapidly compress to its original volume, whereby to restore lumen 105 of two-part stent occluder 90 to its open condition, with the conventional plastically deformable balloon expandable metallic stent holding the lumen open.
- hypoperfusion may also be created in other organs via the intentional occlusion of blood vessels, e.g., hypoperfusion may be created in tumors via the intentional occlusion of the blood vessels servicing those tumors, in order to eradicate or reduce the tumor.
- the blood vessel(s) serving the tumor is (are) intentionally occluded, e.g., in the manner discussed above.
- Uterine fibroids, gastric and/or pancreatic tumors, bleeding gastric and/or duodenal ulcers, etc. are all candidates for the occlusion therapy of the present invention. Still other applications will be apparent to those skilled in the art in view of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Nursing (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Prostheses (AREA)
- Medicines Containing Plant Substances (AREA)
- Surgical Instruments (AREA)
Abstract
A method for inducing weight loss in a patient, the method comprising delivering an apparatus to a target area in the blood vessel. The apparatus includes a first portion for preventing migration of the apparatus from the target area within the blood vessel, and a second portion that remains implanted in the blood vessel after deployment of the apparatus at the target area in the blood vessel and is configured to selectively expand and contract to provide partial or full occlusion of the blood vessel. The method further comprises expanding the second portion of the apparatus to at least partially occlude the blood vessel, allowing a period of time to pass after deployment of the apparatus to the target area in the blood vessel, contracting the second portion, and removing at least the second portion of the apparatus from the blood vessel.
Description
- Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.
- This application claims priority under 35 U.S.C. § 120 and is a divisional of U.S. patent application Ser. No. 15/862,990, entitled “METHOD AND APPARATUS FOR TREATING A PATIENT BY INTENTIONALLY OCCLUDING A BLOOD VESSEL, INCLUDING METHOD AND APPARATUS FOR INDUCING WEIGHT LOSS IN A PATIENT BY INTENTIONALLY OCCLUDING THE CELIAC ARTERY” and filed on Jan. 5, 2018, which is a continuation of U.S. patent application Ser. No. 13/655,354, entitled “METHOD AND APPARATUS FOR TREATING A PATIENT BY INTENTIONALLY OCCLUDING A BLOOD VESSEL, INCLUDING METHOD AND APPARATUS FOR INDUCING WEIGHT LOSS IN A PATIENT BY INTENTIONALLY OCCLUDING THE CELIAC ARTERY” and filed on Oct. 18, 2012, which claims the benefit of U.S. Provisional Application No. 61/548,432, entitled “METHOD AND APPARATUS FOR INDUCING WEIGHT LOSS IN A PATIENT BY INTENTIONALLY OCCLUDING THE CELIAC ARTERY” and filed Oct. 18, 2011, all of which are hereby incorporated by reference in their entireties.
- This invention relates to surgical methods and apparatus in general, and more particularly to surgical and non-surgical methods and apparatus for treating a patient by intentionally occluding a blood vessel, including a catheter-based method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery.
- Obesity is a serious medical condition. Complications associated with obesity include hypertension, diabetes, coronary artery disease, stroke, congestive heart failure, multiple orthopedic problems, pulmonary insufficiency, etc. Obesity can significantly affect quality of life and can result in a markedly decreased life expectancy.
- To date, surgery is the only proven method for inducing substantial long-term weight loss in a patient. Numerous surgical procedures and devices have been developed to induce such weight loss, e.g., “stomach stapling”, the Roux-en-Y (“The Roux”) bypass procedure, the vertical banded gastroplasty (“VBG”) procedure, etc. However, all of the known surgical procedures and devices developed to date for inducing weight loss in a patient suffer from one or more significant disadvantages.
- Accordingly, a new method and apparatus is needed for inducing weight loss in a patient.
- The present invention provides a novel method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery.
- The present invention also provides a novel method and apparatus for inducing weight loss in a patient by intentionally occluding a blood vessel other than the celiac artery, and/or in addition to the celiac artery.
- And the present invention provides a novel method and apparatus for treating a patient for purposes other than inducing weight loss in the patient by intentionally occluding a blood vessel.
- In one preferred form of the present invention, there is provided a method for inducing weight loss in a patient, the method comprising:
-
- intentionally occluding a blood vessel so as to create hypoperfusion in a gastrointestinal organ serviced by the blood vessel, whereby to interfere with normal gastrointestinal function and thereby induce weight loss in a patient.
- In another preferred form of the present invention, there is provided apparatus for occluding a blood vessel comprising a two-part composite stent occluder comprising (i) an exterior, endothelializing support stent, and (ii) an interior, occluding stent comprising a loose weave fabric windsock.
- In another preferred form of the present invention, there is provided apparatus for occluding a blood vessel comprising a two-part composite stent occluder comprising (i) an exterior, endothelializing support stent, and (ii) an interior, progressively-occluding element.
- In another preferred form of the present invention, there is provided a method for providing treatment to a patient, the method comprising:
-
- intentionally occluding a blood vessel so as to create hypoperfusion in tissue serviced by the blood vessel, whereby to interfere with tissue function and thereby treat the patient.
- These and other objects and features of the present invention will be more fully disclosed or rendered obvious by the following detailed description of the preferred embodiments of the invention, which is to be considered together with the accompanying drawings wherein like numbers refer to like parts, and further wherein:
-
FIG. 1 is a schematic view showing one preferred location for occluding the celiac artery in order to induce weight loss in a patient; -
FIG. 2 is a schematic view showing a ligating suture for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient; -
FIG. 3 is a schematic view showing a ligating clip for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient; -
FIG. 4 is a schematic view showing an occluding stent for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient; -
FIG. 4A is a sectional view taken alongline 4A-4A ofFIG. 4 ; -
FIG. 5 is a schematic view showing an occluding umbrella device for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient; -
FIG. 5A is a sectional view taken along line 5A-5A ofFIG. 5 ; -
FIG. 6 is a schematic view showing a two-part composite stent occluder for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient; -
FIGS. 7-10 are schematic views showing deployment of the two-part composite stent occluder ofFIG. 6 ; -
FIGS. 11-13 are schematic views showing withdrawal of the two-part composite stent occluder ofFIG. 6 ; -
FIG. 14 is a schematic view showing a modified form of the two-part composite stent occluder ofFIG. 6 ; -
FIGS. 15 and 16 are schematic views showing another two-part composite stent occluder for occluding the celiac artery (or other target blood vessel) and thereby inducing weight loss in a patient; and -
FIGS. 17 and 18 are schematic views showing the two-part composite stent occluder ofFIGS. 15 and 16 closing down so as to occlude a blood vessel. - The present invention provides a novel method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery.
- The present invention also provides a novel method and apparatus for inducing weight loss in a patient by intentionally occluding a blood vessel other than the celiac artery, and/or in addition to the celiac artery.
- And the present invention provides a novel method and apparatus for treating a patient for purposes other than inducing weight loss in the patient by intentionally occluding a blood vessel.
- In one preferred form of the present invention, weight loss is induced in a patient by intentionally occluding the celiac artery in order to create hypoperfusion in the stomach, whereby to induce weight loss in the patient.
- More particularly, the celiac artery supplies oxygenated blood to the stomach, liver, pancreas, spleen and to the superior half of the duodenum. The celiac artery is a major source of blood for the stomach, inasmuch as the other blood vessels supplying nourishment to the stomach provide adequate flow to maintain viability, but cannot provide the marked increase in blood flow seen in the post-prandial period.
- Accordingly, in one form of the present invention, the celiac artery is intentionally reversibly occluded gradually over time in order to create hypoperfusion in the stomach (and/or other gastrointestinal organs serviced by the celiac artery) so as to interfere with normal gastrointestinal function and thereby induce weight loss in the patient. Occlusion is preferably effected at a location where it will only interfere with gastrointestinal function and will not seriously impede other essential anatomical functions. By way of example but not limitation, and looking now at
FIG. 1 , occlusion may be effected in the trunk of the celiac artery, e.g., at thelocation 5 shown inFIG. 1 . - Alternatively, occlusion may be effected in branches of the celiac artery (e.g., the left or right gastric arteries, the left or right gastroepiploic arteries, the common hepatic artery, and/or other celiac artery branches).
- Furthermore, and also in accordance with the present invention, occlusion may be intentionally induced in other blood vessels servicing the organs of the gastrointestinal tract, whereby to impede normal gastrointestinal function and thereby induce weight loss in the patient. By way of example but not limitation, occlusion may be intentionally induced in other mesenteric vessels (e.g., the superior mesenteric artery and/or its major branches), and/or mesenteric veins, etc.
- In essence, the present invention comprises the intentional occlusion of substantially any blood vessel servicing the gastrointestinal tract such that the occlusion diminishes normal gastrointestinal function, whereby to induce weight loss in the patient. One preferred form of the present invention comprises the intentional occlusion of the celiac artery (including one or more of its branches) so as to diminish gastrointestinal function and thereby induce weight loss in the patient.
- Occlusion may be effected by constricting blood flow through the target blood vessel using an external occluding device, i.e., by applying an external occluding device against the outer surf ace of the blood vessel and causing the blood vessel to close down so as to occlude its internal lumen.
- By way of example but not limitation, and looking now at
FIG. 2 , the target blood vessel may be occluded using aligating suture 10 comprising aknot 15. By way of further example but not limitation, and looking now atFIG. 3 , the target blood vessel may be occluded using a ligatingclip 20. - Or the target blood vessel may be occluded using other external occluding devices which will be apparent to those skilled in the art in view of the present disclosure.
- With such external occluding devices, occlusion is preferably effected by deploying the external occluding device against the exterior surface of the target blood vessel via minimally invasive (e.g., laparoscopic) surgery.
- Occlusion may also be effected by constricting blood flow through the target blood vessel using an internal occluding device, i.e., by deploying an internal occluding device within the internal lumen of a blood vessel so as to restrict blood flow through the internal lumen of the blood vessel.
- By way of example but not limitation, and looking now at
FIGS. 4 and 4A , the target blood vessel may be occluded using an occludingstent 25 which comprises an occludingelement 30 which intrudes across the lumen of the blood vessel which receives the occludingstent 25. - By way of further example but not limitation, and looking now at
FIGS. 5 and 5A , the target blood vessel may be occluded using an erectable “occluding umbrella”device 35 which spans the lumen of the blood vessel. - Or, and looking now at
FIG. 6 , the target blood vessel may be occluded using a two-partcomposite stent occluder 40 comprising (i) an exterior, endothelializing support stent 45 (e.g., comprising askeleton 50 covered by fabric 55), and (ii) an interior, removable occluding stent 60 (e.g., comprising askeleton 65 containing a loose weave fabric “windsock” 70 for clotting off with blood and thereby occluding the blood vessel). In this form of the invention, and looking now atFIGS. 7-10 , the exteriorendothelializing support stent 45 is deployed in the target blood vessel (e.g., the celiac artery) first, and then the interior occludingstent 60 is thereafter deployed within (and removably mounted to) the exteriorendothelializing support stent 45, with the interior occludingstent 60 thereafter clotting off over time. This construction has the advantage that the interior occludingstent 60 can be readily removed from the blood vessel at a later time, whereby to restore blood flow through the blood vessel. See, for example,FIGS. 11-13 , which show withdrawal of the interior occludingstent 60 from the target blood vessel (e.g., the celiac artery). -
FIG. 14 shows a variation of the two-part composite stent occluder ofFIGS. 6-13 , wherein the interior occludingstent 60 comprises theaforementioned skeleton 65 and aninflatable occluding balloon 75 which is disposed withinskeleton 65. In this form of the invention, interior occludingstent 60 is preferably removably disposed within the exteriorendothelializing support stent 45. - Or the target blood vessel may be occluded using other internal occluding devices which will be apparent to those skilled in the art in view of the present disclosure.
- With such internal occluding devices, occlusion is preferably effected by positioning the internal occluding device within the target blood vessel via an endoluminal approach.
- Occlusion of the target blood vessel may be partial or total. Where occlusion is to be partial, the occluding device is configured so as to permit the creation of a partial occlusion, e.g., the ligating
suture 10 ofFIG. 2 and/or theligating clip 20 ofFIG. 3 may be configured to apply just enough force to reduce, but not completely block, blood flow through the target blood vessel; and/or the occludingstent 25 ofFIGS. 4 and 4A , and/or the erectable “occluding umbrella” device ofFIGS. 5 and 5A , and/or the two-partcomposite stent occluder 40 ofFIGS. 6-13 , and/or the two partcomposite stent occluder 40 ofFIG. 14 , may be configured to reduce, but not completely block, blood flow through the target blood vessel. By way of example but not limitation, with the occludingstent 25 ofFIGS. 4 and 4A , occludingelement 30 may includeholes 80, and withumbrella device 35 ofFIGS. 5 and 5A , the umbrella device may include holes 85. Furthermore, with the two-partcomposite stent occluder 40 ofFIGS. 6-13 , the loose weave fabric “windsock” 70 may be configured to clot off only a portion of the lumen of the blood vessel, and/or with the two-partcomposite stent occluder 40 ofFIG. 14 , inflatable occluding balloon 7S may be configured to close off only a portion of the lumen of the blood vessel. - Occlusion may be permanent or temporary. Where occlusion is to be temporary, the occluding device (e.g., the ligating
suture 10 ofFIG. 2 , theligating clip 20 ofFIG. 3 , the occludingstent 25 ofFIGS. 4 and 4A , the erectable “occluding umbrella” device 3S ofFIGS. 5 and 5A , and/or the internal component of the two-partcomposite stent occluder 40 ofFIGS. 6-13 and/orFIG. 14 ) may be configured so that the occluding device is removable at some time in the future, so that normal blood flow through the target blood vessel may be restored. Alternatively, some or all of the occluding devices may be formed out of a biodegradable or bioabsorbable material, so that the occluding device will automatically cease its occlusive function at some time in the future. - The degree of occlusion may also be adjusted over time. By way of example but not limitation, the degree of occlusion may be increased and/or decreased over time, in order to adjust the level of hypoperfusion created in the stomach (and/or other gastrointestinal organ), whereby to selectively adjust the gastrointestinal function of the patient. Thus, if the patient is found to be losing too much weight, the degree of occlusion may be reduced so as to increase gastrointestinal function. Correspondingly, if the patient is found to be losing too little weight, the degree of occlusion may be increased so as to further decrease gastrointestinal function. By way of example but not limitation, a total occlusion may subsequently be partially re-opened or fully re-opened, a partial narrowing can be made more or less restrictive, a restrictive narrowing can be made totally occlusive, etc.
- It is anticipated that different patients will require or tolerate different degrees of narrowing of the target blood vessel. It is also anticipated that patients will generally tolerate greater degrees of narrowing, or better tolerate complete occlusion, if the narrowing is established gradually. This is because gradual occlusion would allow the hypoperfused organ to produce humoral factors to recruit collateral circulation from the adjacent anatomy. This is certainly the case elsewhere in the body where vascular compromise occurs over a prolonged interval, and it is anticipated that it would also be true where occlusion is intentionally created to reduce gastrointestinal function.
- Thus, an occluding device that causes slow progressive occlusion over time may be highly desirable. In one form of the invention, where the occluding device is an external occluding device, this progressive occluding device could be an encircling suture 10 (
FIG. 2 ) and/or ligating clip 20 (FIG. 3 ) containing a hygroscopic material (e.g., Ameroid or the like)—the progressive occluding device could be placed laparoscopically about the exterior surface of the target blood vessel, and the hygroscopic material would then swell over time, resulting in a relatively slow, progressive occlusion of the target blood vessel. In another form of the invention, where the occluding device is an internal occluding device, the progressive occluding device could be an occluding stent 25 (FIGS. 4 and 4A ) and/or an occludingumbrella device 35 containing hygroscopic material that would slowly swell over time, ultimately resulting in vessel narrowing or even complete vessel occlusion. In still another form of the invention, the progressive occluding structure could be a stent containing a diaphanous fiber mesh that slowly clots off and/or endothelializes off over time and becomes occlusive—see, for example, the interior occludingstent 60 ofFIGS. 6-13 , which clots off over time. In these and similar dynamic therapies, the narrowing or occlusive process is initiated at the time of intervention, but takes place over a gradual period of time, the length of which is determined by the nature, design and materials of the progressive occluding device. - The ability to reverse the occlusion or narrowing of the target blood vessel may be important in many situations. In one form of the invention, where the occluding device is an external occluding device, the physician could use laparoscopic instruments to remove the externally compressive or restrictive device (e.g., the encircling
suture 10 ofFIG. 2 , theligating clip 20 ofFIG. 3 , etc.) at a time determined to optimize patient benefit and minimize adverse outcomes. In another form of the invention, where the occluding device is an internal occluding device, the physician could use catheters, wires and inflatable balloons to re-open an occluding stent (e.g., the occludingstent 25 ofFIGS. 4 and 4A ), occluding umbrella (e.g., the occludingumbrella device 35 ofFIGS. 5 and 5A ), endothelialized stent (e.g., with the two-partcomposite stent occluder 40 ofFIGS. 6-13 , or with the two-part composite stent occlude 40 ofFIG. 14 , the interior occluding stent could be removed), etc. In still another form of the present invention, however, the therapy would spontaneously, autonomously and progressively reverse due to the use of biodegradable or bioabsorbable components in the external occluding device and/or the internal occluding device. - In one example of a reversible intra-arterial device, the occluding device comprises the two-part
composite stent occluder 40 ofFIGS. 6-13 in which an exterior stent is first placed in the target blood vessel, with an interior occluding (or gradually occluding) fabric-covered stent thereafter being placed coaxially within the exterior endothelializing support stent (seeFIGS. 7-10 ). The interface between the two components could be designed to block tissue in-growth, so that the two stents could be readily separated at a later time. During a subsequent intervention, the interior occluding stent would be removed (for example, collapsed down into a catheter) and the exterior endothelializing support stent would stay behind in the patient indefinitely (seeFIGS. 11-13 ). - Looking next at
FIGS. 15-18 , there is shown a two-partcomposite stent occluder 90. More particularly, and looking now atFIG. 15 , two-part stent occluder 90 comprises an exterior,endothelializing support stent 95 and an interior, progressively-occludingelement 100 which together form a generally tubular structure having acentral lumen 105 extending therethrough. - Still looking now at
FIG. 15 , exterior,endothelializing support stent 95 preferably comprises acylindrical Nitinol skeleton 110 covered byfabric 115. - Looking next at
FIGS. 15 and 16 , interior, progressively-occludingelement 100 preferably comprises anenvelope 120 formed in the shape of a hollow cylinder and comprising (i) anexterior wall 125 connected to exterior,endothelializing support stent 95, (ii) aninterior wall 130 spaced fromexterior wall 125, (iii) afirst end seal 135, and (iv) asecond end seal 140, whereby to define a cylindrical chamber 145 between exterior andinterior walls first end seal 135 andsecond end seal 140. Chamber 145 is filled with a hygroscopic material 150 (e.g., a shape memory polymer which can absorb many times its own volume in water, so as to thereby dramatically increase in volume). -
Envelope 120 is preferably formed out of a water-impermeable material such as ePTFE (e.g., 2-4 mils thick), and includes a plurality of tiny holes 155 (e.g., 0.05 mils in diameter). Tiny holes 155 permit water (but little else) to very slowly penetrate into chamber 145 and mix withhygroscopic material 150, whereby to expand the volume of thehygroscopic material 150, as will hereinafter be discussed. - In use, and looking now at
FIGS. 16-18 , two-part stent occluder 90 is disposed in the lumen of the blood vessel which is to be occluded (e.g., the celiac artery) so that exterior,endothelializing support stent 95 engages and is secured to the inner wall of the blood vessel. Initially, blood passes easily through lumen central 105 of two-part stent occlude 90. However, over time, water in the blood of the patient passes through the tiny holes 155 inenvelope 120 and enters chamber 145, where it contactshygroscopic material 150. This causes thehygroscopic material 150 to slowly expand to many times its own volume, whereby to progressively occlude thecentral lumen 105 of two-part stent occluder 90 (seeFIGS. 16-18 ). Thus it will be appreciated that, as a result of the foregoing construction, two-part stent occluder 90 can occlude a blood vessel so as to treat a patient (e.g., for weight loss), and this occlusion can be effected on a gradual basis. - If it should thereafter be desired to re-open the occluded blood vessel, a conventional plastically deformable balloon expandable metallic stent (not shown), or any other appropriate stent or stent-like device, may be deployed within the
central lumen 105 of the occluded two-part stent occluder 90. As the conventional plastically deformable balloon expandable metallic stent is expanded, it engages the narrowedinterior wall 130 ofenvelope 120 and drives it radially outward with substantial force. This action applies a compressive force to the water-swollen hygroscopic material 145, thereby forcing water out of the hygroscopic material 145 (e.g., in the manner of squeezing a sponge). By applying a substantial force in a rapid manner,first end seal 135 and/orsecond end seal 140 ofenvelope 120 will rupture at predetermined zones, thereby allowing the hygroscopic material 145 to rapidly compress to its original volume, whereby to restorelumen 105 of two-part stent occluder 90 to its open condition, with the conventional plastically deformable balloon expandable metallic stent holding the lumen open. - It should be appreciated that hypoperfusion may also be created in other organs via the intentional occlusion of blood vessels, e.g., hypoperfusion may be created in tumors via the intentional occlusion of the blood vessels servicing those tumors, in order to eradicate or reduce the tumor. In this case, the blood vessel(s) serving the tumor is (are) intentionally occluded, e.g., in the manner discussed above. Uterine fibroids, gastric and/or pancreatic tumors, bleeding gastric and/or duodenal ulcers, etc. are all candidates for the occlusion therapy of the present invention. Still other applications will be apparent to those skilled in the art in view of the present invention.
- It should be understood that many additional changes in the details, materials, steps and arrangements of parts, which have been herein described and illustrated in order to explain the nature of the present invention, may be made by those skilled in the art while still remaining within the principles and scope of the invention.
Claims (6)
1. A method of at least partially occluding a blood vessel, the method comprising the steps of:
delivering an apparatus to a target area in the blood vessel, the apparatus comprising:
a first portion for preventing migration of the apparatus from the target area within the blood vessel; and
a second portion that remains implanted in the blood vessel after deployment of the apparatus at the target area in the blood vessel and is configured to selectively expand and contract to provide partial or full occlusion of the blood vessel;
expanding the second portion to at least partially occlude the blood vessel;
allowing a period of time to pass after deployment of the apparatus to the target area in the blood vessel;
contracting the second portion; and
removing at least the second portion of the apparatus from the blood vessel.
2. The method of claim 1 , wherein the first portion comprises a stent.
3. The method of claim 1 , wherein the second portion comprises a balloon.
4. The method of claim 1 , wherein the blood vessel is the celiac artery.
5. The method of claim 4 , wherein the target area is a trunk of the celiac artery.
6. The method of claim 1 , wherein the blood vessel is selected from the group consisting of the left gastric artery, the right gastric artery, the left gastroepiploic artery, the right gastroepiploic artery, the common hepatic artery and other celiac artery branches.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/933,651 US20200345374A1 (en) | 2011-10-18 | 2020-07-20 | Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161548432P | 2011-10-18 | 2011-10-18 | |
US13/655,354 US9861369B2 (en) | 2011-10-18 | 2012-10-18 | Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery |
US15/862,990 US10751060B2 (en) | 2011-10-18 | 2018-01-05 | Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery |
US16/933,651 US20200345374A1 (en) | 2011-10-18 | 2020-07-20 | Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/862,990 Division US10751060B2 (en) | 2011-10-18 | 2018-01-05 | Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200345374A1 true US20200345374A1 (en) | 2020-11-05 |
Family
ID=48086485
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/655,354 Active 2032-10-22 US9861369B2 (en) | 2011-10-18 | 2012-10-18 | Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery |
US15/862,990 Active 2033-03-12 US10751060B2 (en) | 2011-10-18 | 2018-01-05 | Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery |
US16/933,651 Abandoned US20200345374A1 (en) | 2011-10-18 | 2020-07-20 | Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/655,354 Active 2032-10-22 US9861369B2 (en) | 2011-10-18 | 2012-10-18 | Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery |
US15/862,990 Active 2033-03-12 US10751060B2 (en) | 2011-10-18 | 2018-01-05 | Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery |
Country Status (7)
Country | Link |
---|---|
US (3) | US9861369B2 (en) |
EP (1) | EP2768424B1 (en) |
BR (1) | BR112014009041B1 (en) |
CA (1) | CA2852266C (en) |
ES (1) | ES2694586T3 (en) |
MX (1) | MX359962B (en) |
WO (1) | WO2013059518A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11273287B2 (en) | 2013-03-08 | 2022-03-15 | Endobar Solutions Llc | Selectively delivering particles into the distal portion of the left gastric artery |
US9572700B1 (en) | 2013-03-08 | 2017-02-21 | Endobar Solutions Llc | Percutaneous endovasular treatment for obesity by selectively delivering particles into the distal portion of the left gastric artery |
US20160022459A1 (en) * | 2013-03-14 | 2016-01-28 | Motarless Technologies Llc | Arterial constrictor for weight loss treatment |
US10010328B2 (en) | 2013-07-31 | 2018-07-03 | NeuVT Limited | Endovascular occlusion device with hemodynamically enhanced sealing and anchoring |
US9681876B2 (en) | 2013-07-31 | 2017-06-20 | EMBA Medical Limited | Methods and devices for endovascular embolization |
WO2015134747A1 (en) * | 2014-03-06 | 2015-09-11 | Mayo Foundation For Medical Education And Research | Apparatus and methods of inducing weight loss using blood flow control |
EP3169251A4 (en) * | 2014-07-20 | 2018-03-14 | Elchanan Bruckheimer | Pulmonary artery implant apparatus and methods of use thereof |
WO2016049162A1 (en) * | 2014-09-26 | 2016-03-31 | Anaxiom Corporation | Removable vascular occlusion device |
CH710439A1 (en) * | 2014-12-18 | 2016-06-30 | Intellistent Ag | Adjustable multi-lumen stent. |
US10716572B2 (en) | 2015-03-20 | 2020-07-21 | Université D'aix-Marseille | Blood flow reducer and method using the same |
US11771434B2 (en) | 2016-09-28 | 2023-10-03 | Restore Medical Ltd. | Artery medical apparatus and methods of use thereof |
CN110691554B (en) | 2017-06-05 | 2022-11-01 | 恢复医疗有限公司 | Double-walled fixed-length stent-like device and method of use |
USD863352S1 (en) * | 2017-07-10 | 2019-10-15 | INTHESMART Inc. | Display screen or portion thereof with graphical user interface |
WO2022035703A1 (en) * | 2020-08-10 | 2022-02-17 | Anaxiom Corporation | Blood flow modification device and methods of using the same |
GB2607878A (en) * | 2021-06-10 | 2022-12-21 | Cook Medical Technologies Llc | Implantable medical device and assembly |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050142163A1 (en) * | 2003-11-10 | 2005-06-30 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5382261A (en) | 1992-09-01 | 1995-01-17 | Expandable Grafts Partnership | Method and apparatus for occluding vessels |
US5522882A (en) * | 1994-10-21 | 1996-06-04 | Impra, Inc. | Method and apparatus for balloon expandable stent-graft delivery |
EP1707233A3 (en) * | 1996-02-02 | 2006-12-20 | Medtronic Vascular, Inc. | Apparatus for blocking flow through blood vessels |
US6086610A (en) * | 1996-10-22 | 2000-07-11 | Nitinol Devices & Components | Composite self expanding stent device having a restraining element |
CA2284720C (en) * | 1997-04-11 | 2006-09-12 | Transvascular, Inc. | Methods and apparatus for transmyocardial direct coronary revascularization |
GB2369575A (en) * | 2000-04-20 | 2002-06-05 | Salviac Ltd | An embolic protection system |
WO2002007795A2 (en) * | 2000-07-24 | 2002-01-31 | Jeffrey Grayzel | Stiffened balloon catheter for dilatation and stenting |
WO2003063729A2 (en) * | 2002-01-28 | 2003-08-07 | Orbus Medical Technologies Inc. | Flared ostial endoprosthesis and delivery system |
US20040044351A1 (en) | 2002-08-27 | 2004-03-04 | Gary Searle | Mechanical occluding device |
US20060009798A1 (en) | 2004-02-02 | 2006-01-12 | Ams Research Corporation | Methods and devices for occluding body lumens and/or enhancing tissue ingrowth |
US9713549B2 (en) | 2004-02-02 | 2017-07-25 | Bayer Healthcare Llc | Contraceptive with permeable and impermeable components |
US7998220B2 (en) * | 2004-02-04 | 2011-08-16 | Murphy Timothy P | Methods for treating obesity |
WO2007006139A1 (en) | 2005-07-12 | 2007-01-18 | Smart Biotech Inc. | Aneurysm occlusion device |
WO2008010197A2 (en) | 2006-07-19 | 2008-01-24 | Novate Medical Limited | A vascular filter |
EP2056747A2 (en) * | 2006-08-17 | 2009-05-13 | NFOCUS Neuromedical Inc. | Isolation devices for the treatment of aneurysms |
US20100185220A1 (en) * | 2007-05-23 | 2010-07-22 | Ic Therapeutics, Inc. | Apparatus and methods for controlled ischemic conditioning |
US9017362B2 (en) * | 2007-06-13 | 2015-04-28 | Cook Medical Technologies Llc | Occluding device |
CN201284009Y (en) * | 2007-06-29 | 2009-08-05 | 庞巴迪动力产品美国公司 | Outboard motor for ship |
US20090318749A1 (en) | 2008-06-19 | 2009-12-24 | Craig Stolen | Method and apparatus for pacing and intermittent ischemia |
ES2536055T3 (en) * | 2010-03-15 | 2015-05-20 | Apollo Endosurgery, Inc. | Bariatric device and weight loss method |
-
2012
- 2012-10-18 ES ES12842548.5T patent/ES2694586T3/en active Active
- 2012-10-18 BR BR112014009041-6A patent/BR112014009041B1/en active IP Right Grant
- 2012-10-18 WO PCT/US2012/060905 patent/WO2013059518A1/en active Application Filing
- 2012-10-18 CA CA2852266A patent/CA2852266C/en active Active
- 2012-10-18 MX MX2014004320A patent/MX359962B/en active IP Right Grant
- 2012-10-18 US US13/655,354 patent/US9861369B2/en active Active
- 2012-10-18 EP EP12842548.5A patent/EP2768424B1/en active Active
-
2018
- 2018-01-05 US US15/862,990 patent/US10751060B2/en active Active
-
2020
- 2020-07-20 US US16/933,651 patent/US20200345374A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050142163A1 (en) * | 2003-11-10 | 2005-06-30 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
Also Published As
Publication number | Publication date |
---|---|
MX2014004320A (en) | 2014-12-05 |
ES2694586T3 (en) | 2018-12-21 |
BR112014009041A2 (en) | 2017-05-23 |
WO2013059518A1 (en) | 2013-04-25 |
CA2852266A1 (en) | 2013-04-25 |
WO2013059518A9 (en) | 2013-06-13 |
EP2768424A4 (en) | 2014-12-24 |
EP2768424B1 (en) | 2018-09-19 |
BR112014009041B1 (en) | 2021-05-25 |
MX359962B (en) | 2018-10-17 |
US20130096580A1 (en) | 2013-04-18 |
CA2852266C (en) | 2019-11-26 |
US10751060B2 (en) | 2020-08-25 |
EP2768424A1 (en) | 2014-08-27 |
US9861369B2 (en) | 2018-01-09 |
US20180146963A1 (en) | 2018-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200345374A1 (en) | Method and apparatus for treating a patient by intentionally occluding a blood vessel, including method and apparatus for inducing weight loss in a patient by intentionally occluding the celiac artery | |
AU2020202927B2 (en) | Occluder and anastomosis devices | |
US10278805B2 (en) | Expandable implant devices for filtering blood flow from atrial appendages | |
RU2514532C2 (en) | Cardiac occluder | |
JP6042889B2 (en) | Cardiac occlusion device | |
JP2017515631A5 (en) | ||
US20100082058A1 (en) | Devices, systems and methods for controlling local blood pressure | |
WO2014135070A1 (en) | Branched covered stent, conveying system comprising same and manufacturing method thereof | |
JP2017524485A (en) | Anastomosis device | |
CN115884801A (en) | Rivet butt-joint platform and plugging device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ANAXIOM CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COHN, WILLIAM E.;DELGADO, REYNOLDS M.;REEL/FRAME:053268/0445 Effective date: 20140228 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |